[Personal View] Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings

Di |2024-09-19T00:30:01+02:00Settembre 19th, 2024|Categorie: Coronavirus Lancet|

Patients infected with antifungal-resistant fungi often do not respond to therapy, substantially increasing mortality risk. Some fungi are inherently resistant to particular antifungals, underscoring the importance of rapid genus identification or, ide...

[Articles] Global, regional, and national burden of upper respiratory infections and otitis media, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021

Di |2024-09-10T00:30:06+02:00Settembre 10th, 2024|Categorie: Coronavirus Lancet|

The findings of this study highlight the widespread burden posed by URIs and otitis media across all age groups and both sexes. There is a continued need for surveillance, prevention, and management to better understand and reduce the burden associated...

[Articles] Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial

Di |2024-09-10T00:30:05+02:00Settembre 10th, 2024|Categorie: Coronavirus Lancet|

In a vaccinated population, people treated with molnupiravir for acute COVID-19 felt better, experienced fewer and less severe COVID-19 associated symptoms, accessed health care less often, and took less time off work at 6 months. However, the absolute...

Torna in cima